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Abstract
Background: Serum 25-hydroxyvitamin D [25(OH)D] is the major circulating form of vitamin D and a standard
indicator of vitamin D status. Emerging evidence in the literature suggests a high prevalence of suboptimal vitamin
D (as defined by serum 25(OH)D levels of <32 ng/ml) as well as an association between lower serum levels and
higher mortality in cancer. We investigated the effect of oral vitamin D supplementation as a means for restoring
suboptimal levels to optimal levels in cancer.
Methods: This is a retrospective observational study of 2198 cancer patients who had a baseline test prior to
initiation of cancer therapy at our hospital to evaluate serum 25(OH)D levels between Jan 08 and Dec 09 as part of
their initial nutritional evaluation. Patients with baseline levels of < = 32 ng/ml (n = 1651) were considered to have
suboptimal serum 25(OH)D levels and were supplemented with 8000 IU of Vitamin D3 (four 2000 IU D3 capsules)
daily as part of their nutritional care plan. The patients were retested at their first follow-up visit. Of 1651 patients,
799 were available for follow up assessment. The mean serum 25(OH)D levels were compared in these 799
patients across the 2 time points (baseline and first follow-up) using paired sample t-test. We also investigated the
factors associated with response to vitamin D supplementation.
Results: Of 2198 patients, 814 were males and 1384 females. 1051 were newly diagnosed and treated at our
hospital while 1147 were diagnosed and treated elsewhere. The mean age at presentation was 55.4 years. The
most common cancer types were breast (500, 22.7%), lung (328, 14.9%), pancreas (214, 9.7%), colorectal (204, 9.3%)
and prostate (185, 8.4%). The mean time duration between baseline and first follow-up assessment was 14.7 weeks
(median 10.9 weeks and range 4 weeks to 97.1 weeks). The mean serum 25(OH)D levels were 19.1 ng/ml (SD =
7.5) and 36.2 ng/ml (SD = 17.1) at baseline and first follow-up respectively; p < 0.001. Patients with prostate and
lung cancer had the highest percentage of responders (70% and 69.2% respectively) while those with colorectal
and pancreas had the lowest (46.7% each). Similarly, patients with serum levels 20-32 ng/ml at baseline were most
likely to attain levels > 32 ng/ml compared to patients with baseline levels < 20 ng/ml.
Conclusions: The response to supplementation from suboptimal to optimal levels was greatest in patients with
prostate and lung cancer as well as those with baseline levels between 20-32 ng/ml. Characteristics of non-
responders as well as those who take longer to respond to supplementation need to be further studied and
defined. Additionally, the impact of improved serum 25(OH)D levels on patient survival and quality of life needs to
be investigated.
Background
A blood calcidiol [25(OH)D] level is the most accepted
way to determine vitamin D status. The appropriate
thresholds to define vitamin D deficiency are debated
with some investigators considering levels < = 32 ng/mL
as “deficient” w h i l eo t h e r sc o n s i d e rt h i sl e v e lt ob e
“suboptimal” [1,2]. The most widely accepted optimal
level of serum 25(OH)D is 35-55 ng/mL [1]. For cancer
prevention, the desirable 25(OH)D levels have been
shown to be 36-48 ng/mL [3].
Hypovitaminosis D has been found to be associated
with a variety of cancers including prostate [4,5], multi-
ple myeloma, colorectal and breast [6]. Some studies
have shown 25(OH)D levels to have an inverse relation
with cancer mortality [7-10] while others consider
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any medium, provided the original work is properly cited.suboptimal levels as a potential risk factor [11]. A study
demonstrated that geographic variation in cancer mor-
tality rates in the US is associated with variations in
solar ultraviolet-B radiation exposure [12]. The evidence
that higher 25(OH)D levels through increased sunlight
exposure or dietary supplement intake inhibit colorectal
carcinogenesis is substantial [13,14]. Biologic evidence
for an association between 25(OH)D and risk for pros-
tate cancer is also reported but the epidemiologic data
have not been definitive [15]. Nevertheless, the available
clinical data suggest that vitamin D influences cancer
prevalence, risk and survival. This provides a sound
rationale for studies that assess 25(OH)D levels in
cancer patients.
Several studies have addressed the impact of vitamin
D supplementation on serum levels of circulating 25
(OH)D in healthy adults [16-19], children [20], older
population, [21,22] lactating women [23], as well as in
patients with rheumatic disease [24], chronic kidney dis-
ease [25], hip fracture [26] and hypovitaminosis [27].
Surprisingly, however, data on the impact of vitamin D
supplementation on circulating 25(OH)D levels in
patients with cancer has not been investigated ade-
quately and many unanswered questions remain [28-30].
The current study has attempted to address the issue of
the effectiveness of vitamin D supplementation as a
means for restoring suboptimal levels to optimal levels
utilizing an oral vitamin D formulation in a large het-
erogeneous population of patients with cancer.
Methods
Study Sample
A retrospective observational study performed on a case
series of 2198 heterogeneous cancer patients treated at
Cancer Treatment Centers of America® (CTCA) at Mid-
western Regional Medical Center (MRMC) between Jan-
uary 2008 and December 2009. Only patients with a
histologically confirmed diagnosis of cancer were
included in this study. This study examined the serum
25(OH)D levels of all new patients presenting to our
institution as part of a routine nutritional status screen-
ing prior to initiation of anticancer therapy. The study
did not restrict patients with respect to treatment his-
tory, tumor histology or stage. The largest cohorts in
the study had a diagnosis of either breast, colorectal,
lung, prostate or pancreatic cancer. This study was
approved by the Institutional Review Board at Midwes-
tern Regional Medical Center (MRMC).
Vitamin D Assessment and Supplementation
All patients underwent a baseline serum 25(OH)D
assessment before undergoing any treatment at our hos-
pital. Serum was collected at the MRMC laboratory,
packed in coolpacks and sent to the Laboratory
Corporation of America (Raleigh, NC) where a chemilu-
minescence immune assay (CLIA, DiaSorin Liasion
assay) was used to measure 25(OH)D. Serum samples
were incubated with antivitamin-D coated microparticles
and isoluminol derivative-conjugated 25(OH)D before
measurement of chemiluminescent signals. Analysis was
completed within 48 hours of collection. The DiaSorin
Liasion 25(OH)D assay has been clinically validated to
be comparable in accuracy and precision to the radioim-
munoassay (RIA). This method uses the same particles
used in the DiaSorin RIA technique. Studies have found
this to be a rapid, accurate, and precise tool for the
measurement of serum 25(OH)D [31,32].
Patients with baseline levels of < = 32 ng/ml (n =
1651) were considered to have suboptimal serum 25
(OH)D levels and were supplemented with 8000 IU of
vitamin D3 (two 2000 IU D3 capsules twice daily with
food) as part of their nutritional care plan [1,33,34]. In
our study, patients were encouraged to use a capsule
form of vitamin D3 which was made available to all
patients through our pharmacy; however, tablet or liquid
formulations were not prohibited. Patients with hyper-
glycemia, history of kidney stones, parathyroid disease,
sarcoidosis and hypercalcemia were not supplemented.
Patients were encouraged to take vitamin D with food
to increase absorption. The patients were retested at
their first follow-up visit. Responders were defined as
those whose 25(OH)D levels reached > 32 ng/mL after
8 weeks of supplementation while non-responders were
those whose 25(OH)D levels remained < = 32 ng/mL
after 8 weeks of supplementation. Supplementation was
continued at 8000 IU/day for another 8 weeks for non-
responders while responders were put on a maintenance
dose of 2000 IU/day. Non-responders were also ques-
tioned about compliance, which was reinforced.
Data Analysis and Statistical Methods
The following covariates were evaluated: type of tumor,
age at presentation, gender, stage at diagnosis and prior
treatment history. Associations between baseline
25(OH)D levels and covariates were assessed using
chi-square test, 2 sample t-t e s t ,A N O V A ,c o r r e l a t i o n
analysis and simple linear regression depending upon
the underlying distribution of the variables evaluated.
V i t a m i nDw a su s e da sb o t hc o n t i n u o u sa sw e l la s
dichotomous variable (< = 32 ng/ml and > 32 ng/ml).
Differences in 25(OH)D levels at baseline and after
treatment with high dose vitamin D supplements were
assessed using paired sample t-test. The distribution of
differences in 25(OH)D levels were examined in relation
to the above covariates using chi-square test, 2 sample
t-test, ANOVA, correlation analysis and simple linear
regression depending upon the underlying distribution
of the variables evaluated. All data were analyzed using
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were two-tailed, and p values were considered signifi-
cant when < 0.05.
Results
Vitamin D at Baseline
2198 patients were tested between January 2008 and
December 2009 at MRMC. Table 1 describes the base-
line characteristics of our patient population stratified
by serum 25(OH)D levels using a cut-off of 32 ng/ml.
Of 2198 patients, 1651 (75.1%) were suboptimal in base-
line serum 25(OH)D (with levels < = 32 ng/ml). Over
70% of both new and previously treated patients were
suboptimal suggesting that the prevalence of suboptimal
levels is not related to treatment history. Colorectal can-
cer patients had the highest prevalence of suboptimal
vitamin D (85.3%) while breast cancer patients had the
lowest (69.4%). Table 2 compares the mean values of
baseline serum 25(OH)D across different types of can-
cers. Consistent with the results reported in Table 1,
patients with breast cancer were found to have the high-
est average 25(OH)D levels of 27.9 ng/ml whereas those
with colorectal cancer were found to have the lowest
average of 21.6 ng/ml. When comparing the mean
values of baseline serum 25(OH)D across gender, prior
treatment history and stage at diagnosis, we found no
statistically significant relationship between any of these
covariates and serum 25(OH)D levels. Finally, there was
no correlation between age at presentation and baseline
25(OH)D levels (Pearson r = 0.014, p = 0.52).
Vitamin D at First Follow-up
Of 1651 patients who had suboptimal serum 25(OH)D
levels at baseline, 799 were available for follow up
Table 1 Baseline patient characteristics (N = 2198)
Characteristic Serum 25(OH)D levels
p-value
< = 32 ng/ml (n = 1651) > 32 ng/ml (n = 547)
Gender
Males 628 (77.1) 186 (22.9) Chi-square
Females 1023 (73.9) 361 (26.1) 0.09
Age at Presentation
Mean 55.2 55.7 2 sample t-test
Median 55.9 55.8 0.32
Range 18.6 - 92.1 21.1 - 89.6
Treatment history
Newly Diagnosed 769 (73.2) 282 (26.8) Chi-square
Previously Treated 882 (76.9) 265 (23.1) 0.04
Cancer Site
Breast 347 (69.4) 153 (30.6)
Lung 268 (81.7) 60 (18.3)
Pancreas 157 (73.4) 57 (26.6) Chi-square
Colorectal 174 (85.3) 30 (14.7) < 0.001
Prostate 132 (71.4) 53 (28.6)
Others 573 (74.7) 194 (25.3)
Stage at Diagnosis
Stage 0 21 (75) 7 (25)
Stage 1 194 (73.2) 71 (26.8)
Stage 2 332 (73.8) 118 (26.2) Chi-square
Stage 3 394 (76.7) 120 (23.3) 0.76
Stage 4 566 (74.8) 191 (25.2)
Indeterminate 144 (78.3) 40 (21.7)
SD = Standard Deviation; Numbers in parenthesis for cancer site, gender, treatment history and stage at diagnosis are row percentages
Table 2 Mean baseline serum 25(OH)D levels stratified by
top 5 cancer sites (N = 2198)




All Cancers (n = 2198) 25.1 15.1
Breast (n = 500) 27.9 17.6
Lung (n = 328) 22.7 11.9
Pancreas (n = 214) 24.4 15.3 < 0.001
Colorectal (n = 204) 21.6 11.4
Prostate (n = 185) 26.8 14.6
Others (n = 767) 25.0 15.0
SD = Standard Deviation
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available for first follow-up (n = 799) differed from those
not available (n = 852) with regard to several baseline
characteristics such as cancer type, stage, gender and treat-
ment history as reported in Table 3. The mean time dura-
tion between baseline and first follow-up assessment was
14.7 weeks (median 10.9 weeks and range 4 weeks to 97.1
weeks). There were no episodes of intolerance to vitamin
D and no toxicity was reported or observed in any patient.
Of 799 patients, 441 (55.2%) were responders and 358
(44.8%) were non-responders at first follow-up. Supple-
mentation was continued at 8000 IU/day for another
8 weeks for non-responders while responders were put on
a maintenance dose of 2000 IU/day. The results for second
follow-up after 8 weeks are not available yet and therefore
not included in the present analysis. Table 4 compares the
mean scores of 25(OH)D at baseline and first follow-up in
these 799 patients for all cancers combined as well as stra-
tified by the top 5 cancer sites. The difference in means
across the two time points was statistically significant in
the total sample as well as within each stratum of cancer
type. The highest improvement in mean serum levels was
observed in lung cancer patients (22.7) while lowest
improvement was seen in colorectal cancer patients (13.2),
the difference being statistically significant.
Factors Associated with Response to Supplementation
Table 5 compares responders versus non-responders
with regard to cancer type, gender, prior treatment his-
tory, stage at diagnosis and baseline 25(OH)D levels.
Patients with prostate and lung cancer had the highest
percentage of responders (70% and 69.2% respectively)
while those with colorectal and pancreas had the lowest
(46.7% each). The distribution of responders versus
non-responders did not differ by gender, treatment his-
tory and stage at diagnosis. Age at presentation was
positively and weakly correlated with improvement in
25(OH)D levels (Pearson r = 0.08, p = 0.02). Interest-
ingly, baseline 25(OH)D levels were a strong predictor
of improvement in serum levels such that lower values
at baseline were correlated with a higher improvement
(Pearson r = -0.20, p < 0.001). Upon simple linear
regression analysis, every 1 ng/mL decrease in baseline
vitamin D level was associated with an improvement of
0.44 ng/mL (95% CI: 0.29 - 0.60 ng/mL) at first follow-up.
However, when we compared the distribution of
responders across three categories of baseline 25(OH)
D levels, we found that patients with serum levels 20-
32 ng/ml at baseline were most likely to attain levels >
32 ng/ml compared to patients with baseline levels <
20 ng/ml.
Table 3 Comparison of baseline characteristics of patients available for follow-up versus those not available
Characteristic Patients with follow-up data (N = 799) Patients without follow-up data (N = 852) p-value
Mean age at presentation (SD) 55.0 (9.8) 55.5 (10.1) 2 sample t-test
0.37
Cancer Site
Breast 182 (52.4) 165 (47.6)
Lung 120 (44.8) 148 (55.2)
Pancreas 60 (38.2) 97 (61.8) Chi-square
Colorectal 90 (51.7) 84 (48.3) 0.03
Prostate 60 (45.5) 72 (54.5)
Others 287 (50.1) 286 (49.9)
Gender
Males 266 (42.4) 362 (57.6) Chi-square
Females 533 (52.1) 490 (47.9) < 0.001
Treatment History
Newly Diagnosed 410 (53.3) 359 (46.7) Chi-square
Previously Treated 389 (44.1) 493 (55.9) < 0.001
Stage at Diagnosis
Stage 0 8 (38.1) 13 (61.9)
Stage 1 106 (54.6) 88 (45.4)
Stage 2 164 (49.4) 168 (50.6) Chi-square
Stage 3 208 (52.8) 186 (47.2) 0.02
Stage 4 244 (43.1) 322 (56.9)
Indeterminate 69 (47.9) 75 (52.1)
SD = Standard Deviation
Numbers in parenthesis for cancer site, gender, treatment history and stage at diagnosis are row percentages
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Vitamin D has been hypothesized to have an association
with cancer risk and survival, and several studies in the
literature document a high prevalence of vitamin D defi-
ciency in cancer patients [35-39]. Although vitamin D
deficiency is now more recognized in the oncology
population, relatively less is known about patients’
response to supplementation, dosing regimens, and
overall benefits other than bone health. The current
study was undertaken to investigate the effectiveness of
oral vitamin D supplementation to restore suboptimal
serum 25(OH)D levels in a large heterogeneous popula-
tion of patients with cancer.
The response to supplementation (in terms of restora-
tion from suboptimal levels to optimal levels) was most
pronounced in patients with lung and prostate cancer
and least in those with colorectal and pancreatic cancer.
Consistent with the above findings, we also observed
Table 4 Comparison of mean serum 25(OH)D levels at baseline and first follow-up stratified by top 5 cancer sites
(N = 799)
Site of tumor Baseline
Mean 25(OH)D in ng/mL (SD)
Follow-up
Mean 25(OH)D in ng/mL (SD)
Paired t-test
p-value
All Cancers (n = 799) 19.1 (7.5) 36.2 (17.1) < 0.001
Breast (n = 182) 19.7 (8.0) 37.6 (16.8) < 0.001
Lung (n = 120) 18.4 (7.3) 41.1 (18.9) < 0.001
Pancreas (n = 60) 16.2 (7.7) 30.8 (14.2) < 0.001
Colorectal (n = 90) 18.7 (7.7) 31.9 (16.2) < 0.001
Prostate (n = 60) 20.2 (6.9) 42.1 (15.9) < 0.001
Others (n = 287) 19.5 (7.1) 34.6 (16.8) < 0.001
SD = Standard Deviation
Table 5 Comparison of responders versus non-responders with regard to cancer type, gender, prior treatment history,
stage at diagnosis and baseline 25(OH)D levels (N = 799)
Characteristic Responders (n = 441) Non-responders (n = 358) Chi-square
p-value
Cancer Site
Breast 103 (56.6) 79 (43.4)
Lung 83 (69.2) 37 (30.8)
Pancreas 28 (46.7) 32 (53.3) < 0.001
Colorectal 42 (46.7) 48 (53.3)
Prostate 42 (70) 18 (30)
Others 143 (49.8) 144 (50.2)
Gender
Males 153 (57.5) 113 (42.5) 0.35
Females 288 (54.0) 245 (46.0)
Treatment History
Newly Diagnosed 233 (56.8) 177 (43.2) 0.34
Previously Treated 208 (53.5) 181 (46.5)
Stage at Diagnosis
Stage 0 3 (37.5) 5 (62.5)
Stage 1 56 (52.8) 50 (47.2)
Stage 2 91 (55.5) 73 (44.5) 0.82
Stage 3 117 (56.3) 91 (43.8)
Stage 4 139 (57) 105 (43)
Indeterminate 35 (55.2) 34 (44.8)
Baseline serum 25(OH)D
< 12 ng/ml 55 (35.3) 101 (64.7)
12-20 ng/ml 145 (55.1) 118 (44.9) < 0.001
20-32 ng/ml 241 (63.4) 139 (36.6)
Numbers in parenthesis are row percentages
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absolute increase in patients with lung and prostate can-
cer while those with colorectal cancer recorded the low-
est absolute improvement. One potential explanation on
why patients with colorectal cancer showed less benefit
as compared to those with lung cancer could be the
more severe gastrointestinal toxicity (stomatitis and
diarrhea) associated with chemotherapy regimens for
colorectal cancer [36]. Severe stomatitis could have an
effect on compliance or ability to take an oral supple-
ment, while severe diarrhea could impact intake as well
as absorption. This explanation seems to be consistent
with the findings from a study which observed an asso-
ciation between chemotherapy and a significant increase
in the risk of severe vitamin D deficiency in colorectal
cancer patients [36]. The study hypothesized that che-
motherapy administration in colorectal cancer might
result in dietary modifications such as reduction or
elimination of milk products as part of the management
of chemotherapy- induced diarrhea. It also surmised
that patients undergoing chemotherapy might not
absorb dietary vitamin D well due to subclinical mucosi-
tis [36]. As a result, these patients may need higher
amounts of supplementation for a longer period of time
in order to achieve adequate serum 25(OH)D status.
Future studies should evaluate response to supplementa-
tion in relation to different chemotherapy regimens.
The response to supplementation from suboptimal to
optimal levels was greatest in patients with baseline 25
(OH)D levels between 20-32 ng/ml as compared to
those below 20 ng/ml. Also, vitamin D supplementation
resulted in a significant absolute increase in serum 25
(OH)D levels particularly in patients with lower levels at
baseline. This is not surprising because patients with
lower baseline levels have to cover a greater ground to
convert from suboptimal to optimal levels. On the other
hand, those with higher baseline levels are more likely
to convert. The observation of highest absolute improve-
ment in serum 25(OH)D in those with lowest baseline
levels is also corroborated by previous research con-
ducted in different patient populations including elderly,
premenopausal and healthy individuals which found that
participants with lower baseline serum 25(OH)D con-
centrations had a stronger serum 25(OH)D response to
supplementation [40-44]. It has been hypothesized that
hydroxylation of vitamin D3 to 25(OH)D is likely a
saturable process, causing an attenuated response to
supplementation in individuals with higher baseline
serum 25(OH)D concentrations [45].
In order to put our study in context, we review here
3 studies in breast cancer that have evaluated the impact
of vitamin D supplementation on serum 25(OH)D
levels. Crew et al. examined the effects of standard-dose
vitamin D supplementation on serum 25(OH)D levels in
breast cancer patients. They observed that cholecalci-
ferol 400 IU daily for 1 year raised serum 25(OH)D
levels only modestly, by less than 3 ng/mL in only a
small percentage of premenopausal women (< 15%).
Although the RDA of vitamin D in premenopausal
women is only 200 IU daily, their study suggested that a
dose of 400 IU daily was inadequate in breast cancer
patients, even to maintain skeletal health, and was prob-
ably too low for meaningful anticancer effects [28].
The other study conducted on breast cancer patients
by Khan et al. reported the safety and efficacy of vita-
min D supplementation using 50,000 IU weekly on
postmenopausal women. They studied the effect of
vitamin D-ss (standard supplementation) and vitamin
D-HD (high dose) supplementation on serum 25(OH)D
levels. According to them vitamin D-HD for 12 weeks
is extremely effective in optimizing 25(OH)D levels and
results in a predictable increase in 25(OH)D levels.
Comparing women who received vitamin D-HD versus
vitamin D-ss, the former displayed statistically signifi-
cant higher values. Moreover, vitamin D-HD was safe
in this population, with no cases of hypercalcemia or
renal stones. Their results also suggested that 50,000
IU of vitamin D3, when given weekly to post-menopau-
sal women starting adjuvant letrozole, resulted in clini-
cally significant improvement in disability from joint
symptoms [29].
A more recent data published by Nogues et al.
reported a prevalence of 85-92% of vitamin D deficiency
(defined as < 30 ng/ml) in breast cancer patients as
compared to 74% reported by Crew et al. (defined as <
20 ng/ml) and 63% by Khan et al (defined as < 20 ng/
ml). In this study, treatment with 16,000 IU of vitamin
D every 2 weeks increased vitamin D plasma levels sig-
nificantly in about 76.52% of subjects with baseline vita-
min D deficiency (plasma levels < 30 ng/ml) over
3 months follow up. However, few subjects had baseline
25(OH)D levels ≥ 30 ng/ml and were prescribed the
normal daily calcium and vitamin D supplements (800
IU) and their 25(OH)D levels did not increase signifi-
cantly [30].
T h ed o s a g eu s e df o rv i t a m i nDs u p p l e m e n t a t i o ni n
our study was 8000 IU/d, consistent with the data from
H o l i c kM Fo f5 0 , 0 0 0I Uw e e k l y[ 3 3 ] ,w h i c hl e dt oa n
increase in the mean serum 25(OH)D levels from 19.1
ng/ml to 36.2 ng/ml. No safety concerns were reported.
When comparing it with the vitamin D dose response in
healthy individuals, the literature yielded the following
results. Talwar et al. showed that supplementation with
800 IU/d vitamin D3 in postmenopausal African Ameri-
can women raised the mean serum 25(OH)D concentra-
tion from a baseline of 18.7+/-8.2 ng/mL to 28.5+/-8.6
ng/mL at a 3 month interval [46]. In another study,
Barger-Lux et al. showed that in a relatively replete
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an increase of 5.2 ng/mL from a mean of 26.8 to 32 ng/
mL [45]. Likewise Heaney et al reported a dose response
of 0.28 ng/mL per 1 μg/40IU oral vitamin D3 supplemen-
ted [47]. Furthermore, Aloia et al. undertook a dose-find-
ing study in African American and white men and
women with the objective of investigating an algorithm
for raising 25(OH)D concentrations to between 32 and
56 ng/mL. They suggested a dose of 3800 IU for those
above a 25(OH)D threshold of 22 ng/mL and a dose of
5000 IU for those below that threshold [16].
Our study has some limitations. This study, because of
its retrospective nature, relies on data not primarily
meant for research. As a result, we could not adjust for
several potential confounding factors that could have
influenced serum 25(OH)D levels. For example, we did
not adjust for season of blood draw in our analyses.
Therefore, increase in serum 25(OH)D levels between
baseline and first follow-up could have been influenced
by change in season of blood draw, especially since the
time between assessments could have put a patient into a
different season by the first assessment. Moreover, we
did not have information on intake of vitamin D or data
regarding their typical sun exposure which could have
shed further light on the subjects’ vitamin D status. How-
ever, our patients reside in all areas of the United States.
Other variables such as race, physical activity, BMI and
chemotherapy received known to have a significant rela-
tionship with 25(OH)D status were not controlled for in
the analyses. Without a control group, it is less clear
whether vitamin D insufficiency preceded the diagnosis
of cancer or whether it was associated with the disease
process. We did not collect information about compli-
ance with vitamin D supplementation, which may be an
important element to understand the response to vitamin
D supplements in certain individuals. For some non-
responders that were questioned about compliance,
compliance was an issue, as well as the type of vitamin D
supplement that was being used. On at least one occa-
sion, a patient taking hard tablets did not respond, and
subsequently responded when switched to a capsule.
This raises another limitation of our study. In our study,
patients were encouraged to use a capsule form of vita-
min D3, however, some did choose to use tablets or
liquids. The time to first follow-up was not uniform due
to differences in medical treatment regimens, and there
were several losses to follow-up in the study. This is
because many patients decided not to get treated at our
hospital after their initial evaluation. Also some patients
could not return for follow up due to the advanced nat-
ure of their disease or death. A poor follow-up rate of
48.4% introduces selection bias into the study because
patients available for first follow-up (n = 799) differed
from those not available (n = 852) with regard to several
baseline characteristics such as cancer type, stage, gender
and treatment history. Since 25(OH)D assays were mea-
sured in real-time rather than batches in a central labora-
tory, this may introduce batch to batch variability in the
assays. Most of the literature on vitamin D and cancer
(including our study) is largely based upon observational
data. Therefore, rigorous clinical trials are needed before
we can make broad recommendations about high-dose
supplementation to our patients.
There are several clinical implications of this work
such as the need to monitor the vitamin D intake and
serum 25(OH)D levels in patients with cancer and sup-
plementation of vitamin D in those who are found to
have suboptimal levels. Vitamin D insufficiency is preva-
lent in this population and should be routinely assessed,
especially in breast and prostate cancer patients where
the treatment for these diseases also has an impact on
long-term bone health. There was a significantly lower
response to supplementation in individuals with colorec-
tal and pancreatic cancers, suggesting these individuals
may need higher doses of supplementation for longer
periods of time and/or may have a higher rate of non-
compliance. As a result, assessing and monitoring com-
pliance to oral supplementation is critical in colorectal
and pancreatic cancer patients where oral intake and
absorption may be compromised. Further studies evalu-
ating the higher dose given just once weekly may help
answer the question of whether compliance and/or
absorption contributes to a less than average response
in patients with colorectal cancer. Determining the
effects of achieving and maintaining adequate 25(OH)D
levels with supplementation on patient outcomes is also
an important research avenue.
Conclusions
We found oral vitamin D formulation of 8000 IU/d for
8 weeks to be a safe regimen to correct vitamin D insuf-
ficiency in this oncology population. The response to
supplementation from suboptimal to optimal levels was
greatest in patients with prostate and lung cancer as
well as those with baseline levels between 20-32 ng/ml
and lowest in those with colorectal and pancreatic can-
cer as well as those with baseline levels below 20 ng/ml.
Characteristics of non-responders as well as those who
take longer to respond to supplementation need to be
further studied and defined. Additionally, the impact of
improved serum 25(OH)D levels on patient survival and
quality of life needs to be investigated. Further prospec-
tive studies are needed in this direction.
Acknowledgements
This study was funded by Cancer Treatment Centers of America®. We thank
Gwendolynn M. Lambert, Anna Torpe and John Birdsall for assistance with
data collection for this project.
Vashi et al. Nutrition Journal 2010, 9:60
http://www.nutritionj.com/content/9/1/60
Page 7 of 9Authors’ contributions
PGV was the main author of the manuscript, participated in concept, design,
writing and data interpretation. KT and CAL participated in concept, design,
data collection and writing. DPB participated in concept, design and data
interpretation. DG participated in concept, statistical analysis, data
interpretation and writing. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 27 May 2010 Accepted: 23 November 2010
Published: 23 November 2010
References
1. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R:
Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713-716.
2. Hollis BW: Circulating 25-hydroxyvitamin D levels indicative of vitamin D
sufficiency: implications for establishing a new effective dietary intake
recommendation for vitamin D. J Nutr 2005, 135:317-322.
3. Bischoff-Ferrari HA: Optimal serum 25-hydroxyvitamin D levels for
multiple health outcomes. Adv Exp Med Biol 2008, 624:55-71, 55-71.
4. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL,
Hollis BW, Huang WY, Shikany JM, Hayes RB: Serum Vitamin D
Concentration and Prostate Cancer Risk: A Nested Case-Control Study. J
Natl Cancer Inst 2008, 100(11):796-804.
5. Mucci LA, Spiegelman D: Vitamin D and Prostate Cancer Risk–A Less
Sunny Outlook? J Natl Cancer Inst 2008, 100(11):759-61.
6. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D,
Chang-Claude J: Serum 25-hydroxyvitamin D and risk of post-
menopausal breast cancer–results of a large case-control study.
Carcinogenesis 2008, 29:93-99.
7. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, Asomaning K, Hollis BW,
Lynch TJ, Wain JC, Giovannucci E, Christiani DC: Circulating 25-
hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-
small-cell lung cancer. J Clin Oncol 2008, 26:5596-5602.
8. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL,
Fuchs CS: Circulating 25-hydroxyvitamin d levels and survival in patients
with colorectal cancer. J Clin Oncol 2008, 26:2984-2991.
9. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE: Association between
serum 25(OH)D and death from prostate cancer. Br J Cancer 2009,
100:450-454.
10. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC,
Lynch TJ, Giovannucci E, Su L, Christiani DC: Circulating 25-hydroxyvitamin
D levels predict survival in early-stage non-small-cell lung cancer
patients. J Clin Oncol 2007, 25:479-485.
11. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J,
Albanes D: A prospective nested case-control study of vitamin D status
and pancreatic cancer risk in male smokers. Cancer Res 2006,
66:10213-10219.
12. Grant WB: An estimate of premature cancer mortality in the U.S. due to
inadequate doses of solar ultraviolet-B radiation. Cancer 2002,
94:1867-1875.
13. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW,
Giovannucci EL: Plasma vitamin D metabolites and risk of colorectal
cancer in women. Cancer Epidemiol Biomarkers Prev 2004, 13:1502-1508.
14. Pritchard RS, Baron JA, Gerhardsson dV: Dietary calcium, vitamin D, and
the risk of colorectal cancer in Stockholm, Sweden. Cancer Epidemiol
Biomarkers Prev 1996, 5:897-900.
15. Giovannucci E: The epidemiology of vitamin D and cancer incidence and
mortality: a review (United States). Cancer Causes Control 2005, 16:83-95.
16. Aloia JF, Patel M, Dimaano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S,
Yeh JK: Vitamin D intake to attain a desired serum 25-hydroxyvitamin D
concentration. Am J Clin Nutr 2008, 87:1952-1958.
17. Barnes MS, Robson PJ, Bonham MP, Strain JJ, Wallace JM: Effect of vitamin
D supplementation on vitamin D status and bone turnover markers in
young adults. Eur J Clin Nutr 2006, 60:727-733.
18. Malhotra N, Mithal A, Gupta S, Shukla M, Godbole M: Effect of vitamin D
supplementation on bone health parameters of healthy young Indian
women. Arch Osteoporos 2009, 4:47-53.
19. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D3
(cholecalciferol) supplementation on fractures and mortality in men and
women living in the community: randomised double blind controlled
trial. BMJ 2003, 326:469.
20. Ambroszkiewicz J, Klemarczyk W, Gajewska J, Chelchowska M, Strucinska M,
Oltarzewski M, Laskowska-Klita T: [Effect of vitamin D supplementation on
serum 25-hydroxyvitamin D and bone turnover markers concentrations
in vegetarian children]. Med Wieku Rozwoj 2009, 13:34-39.
21. Blum M, Dallal GE, Dawson-Hughes B: Body size and serum 25 hydroxy
vitamin D response to oral supplements in healthy older adults. JA m
Coll Nutr 2008, 27:274-279.
22. Nugent C, Roche K, Wilson S, Fitzgibbon M, Griffin D, Nichaidhin N,
Mulkerrin E: The effect of intramuscular vitamin D (cholecalciferol) on
serum 25OH vitamin D levels in older female acute hospital admissions.
Ir J Med Sci 2010, 179:57-61.
23. Basile LA, Taylor SN, Wagner CL, Horst RL, Hollis BW: The effect of high-
dose vitamin D supplementation on serum vitamin D levels and milk
calcium concentration in lactating women and their infants. Breastfeed
Med 2006, 1:27-35.
24. von Restorff C, Bischoff-Ferrari HA, Theiler R: High-dose oral vitamin D3
supplementation in rheumatology patients with severe vitamin D3
deficiency. Bone 2009, 45:747-749.
25. Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon AW: Vitamin D
insufficiency and treatment with oral vitamin D3 in northern-dwelling
patients with chronic kidney disease. J Nephrol 2009, 22:75-82.
26. Glendenning P, Chew GT, Seymour HM, Gillett MJ, Goldswain PR, Inderjeeth CA,
Vasikaran SD, Taranto M, Musk AA, Fraser WD: Serum 25-hydroxyvitamin D
levels in vitamin D-insufficient hip fracture patients after supplementation
with ergocalciferol and cholecalciferol. Bone 2009, 45:870-875.
27. Goswami R, Gupta N, Ray D, Singh N, Tomar N: Pattern of 25-hydroxy
vitamin D response at short (2 month) and long (1 year) interval after 8
weeks of oral supplementation with cholecalciferol in Asian Indians with
chronic hypovitaminosis D. Br J Nutr 2008, 100:526-529.
28. Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL: High
prevalence of vitamin D deficiency despite supplementation in
premenopausal women with breast cancer undergoing adjuvant
chemotherapy. J Clin Oncol 2009, 27:2151-2156.
29. Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, Klemp JR,
Fabian CJ: Effect of vitamin D supplementation on serum 25-hydroxy
vitamin D levels, joint pain, and fatigue in women starting adjuvant
letrozole treatment for breast cancer. Breast Cancer Res Treat 2010,
119:111-118.
30. Nogues X, Servitja S, Pena MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L,
Albanell J, Diez-Perez A, Tusquets I: Vitamin D deficiency and bone
mineral density in postmenopausal women receiving aromatase
inhibitors for early breast cancer. Maturitas 2010, 66(3):291-7.
31. Wootton AM: Improving the measurement of 25-hydroxyvitamin D. Clin
Biochem Rev 2005, 26:33-36.
32. Ersfeld DL, Rao DS, Body JJ, Sackrison JL, Miller AB, Parikh N, Eskridge TL,
Polinske A, Olson GT, MacFarlane GD: Analytical and clinical validation of
the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin
Biochem 2004, 37:867-874.
33. Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
34. Bischoff-Ferrari H: Vitamin D: what is an adequate vitamin D level and
how much supplementation is necessary? Best Pract Res Clin Rheumatol
2009, 23:789-795.
35. Everett PC: The prevalence of vitamin D deficiency and insufficiency in a
hematology-oncology clinic. Clin J Oncol Nurs 2008, 12:33-35.
36. Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY:
Chemotherapy is linked to severe vitamin D deficiency in patients with
colorectal cancer. Int J Colorectal Dis 2009, 24:219-224.
37. Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, McTiernan A,
Bernstein L, Wayne S, Gilliland F, Baumgartner K, Baumgartner R, Ballard-
Barbash R: Vitamin D insufficiency in a multiethnic cohort of breast
cancer survivors. Am J Clin Nutr 2008, 88:133-139.
38. Wang-Gillam A, Miles DA, Hutchins LF: Evaluation of vitamin D deficiency in
breast cancer patients on bisphosphonates. Oncologist 2008, 13:821-827.
39. Zhou G, Stoitzfus J, Swan BA: Optimizing vitamin D status to reduce
colorectal cancer risk: an evidentiary review. Clin J Oncol Nurs 2009, 13:
E3-E17.
Vashi et al. Nutrition Journal 2010, 9:60
http://www.nutritionj.com/content/9/1/60
Page 8 of 940. Canto-Costa MH, Kunii I, Hauache OM: Body fat and cholecalciferol
supplementation in elderly homebound individuals. Braz J Med Biol Res
2006, 39:91-98.
41. DeLappe E, McGreevy C, ni Chadhain N, Grimes H, O’Brien T, Mulkerrin E:
Vitamin D insufficiency in older female community-dwelling acute
hospital admissions and the response to supplementation. Eur J Clin Nutr
2006, 60:1009-1015.
42. Harris SS, Dawson-Hughes B: Plasma vitamin D and 25OHD responses of
young and old men to supplementation with vitamin D3. J Am Coll Nutr
2002, 21:357-362.
43. Nelson ML, Blum JM, Hollis BW, Rosen C, Sullivan SS: Supplements of 20
microg/d cholecalciferol optimized serum 25-hydroxyvitamin D
concentrations in 80% of premenopausal women in winter. J Nutr 2009,
139:540-546.
44. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R: Evidence that
vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than
does vitamin D2. Am J Clin Nutr 1998, 68:854-858.
45. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF: Vitamin D and its
major metabolites: serum levels after graded oral dosing in healthy
men. Osteoporos Int 1998, 8:222-230.
46. Talwar SA, Aloia JF, Pollack S, Yeh JK: Dose response to vitamin D
supplementation among postmenopausal African American women. Am
J Clin Nutr 2007, 86:1657-1662.
47. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ: Human serum
25-hydroxycholecalciferol response to extended oral dosing with
cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
doi:10.1186/1475-2891-9-60
Cite this article as: Vashi et al.: Impact of oral vitamin D
supplementation on serum 25-hydroxyvitamin D levels in oncology.
Nutrition Journal 2010 9:60.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vashi et al. Nutrition Journal 2010, 9:60
http://www.nutritionj.com/content/9/1/60
Page 9 of 9